Activators & Inhibitors

UDP-xylose disodium is a nature product that could be isolated from Cryptococcus laurentii (N RRL Y-1401). UDP-xylose disodium is a metabolite in the nucleotide sugar metabolism [1] .

Crocin IV (Dicrocin), a crocetin glycoside from the carotenoid pigments, exhibits significant antioxidant activity [1].

Invertase is a major enzyme present in plants and microorganisms , is often used in biochemical studies. Invertase catalyzes the hydrolysis of the disaccharide sucrose into glucose and fructose [1] .

Abrilumab, a fully human monoclonal antibody, targets the α4β7 integrin heterodimer, selectively binding to it. This specificity makes it a potential research tool for investigating inflammatory bowel disease (IBD) [1].

Tebentafusp (IMCgp100) is a bispecific fusion protein targeting the gp100 peptide-HLA-A*02:01 complex, a melanoma-associated antigen, by directing T cells toward melanoma cells expressing gp100 through a high-affinity T-cell receptor (TCR) binding domain coupled with an anti-CD3 domain, promoting T-cell engagement, inflammatory cytokine production, and cytolytic protein release, leading to direct tumor cell lysis [1] [2].

Sotrovimab (VIR 7831), a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), effectively neutralizes SARS-CoV-2, SARS-CoV-1, and various other sarbecoviruses. Developed from S309, it possesses a prolonged half-life and excellent bioavailability within the respiratory mucosa. Its mechanism potentially facilitates immune-mediated viral elimination, thereby averting the advancement of Covid-19 during the disease's early stages [1][2].

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody (bsAb) targeting the SSTR2 and CD3 domains to bind somatostatin receptor 2 (SSTR2) and T cells, respectively. Featuring a full Fc domain for extended serum half-life, it engages in the targeted elimination of SSTR2-positive tumor cells via redirected T cell-mediated cytotoxicity (RTcC) [1].

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody (bsAb) targeting the SSTR2 and CD3 domains to bind somatostatin receptor 2 (SSTR2) and T cells, respectively. Featuring a full Fc domain for extended serum half-life, it engages in the targeted elimination of SSTR2-positive tumor cells via redirected T cell-mediated cytotoxicity (RTcC) [1].

Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. This compound shows potential in treating pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, and multiple myeloma (MM) osteolytic lesions [1] [2] [3] [4] [5].